Lifestyle

Clinical Articles iconClinical Articles

With obesity demonstrating mortality rates comparable to cigarette smoking and obstructive sleep apnoea (OSA) potentially affecting up to one billion people worldwide, the intersection of these conditions demands innovative therapeutic approaches. Recent advances in incretin-based therapies, particularly the GLP-1/GIP receptor agonist tirzepatide (Mounjaro), are revolutionising treatment for patients with concurrent obesity and OSA, offering clinically significant improvements that may challenge traditional CPAP-centric management strategies.

Upcoming Healthed Webcast

Panel Discussion on The Role of GLP-1 in the Management of CKD in T2D

Tuesday 17th March, 7pm - 9pm AEDT

Speakers

Dr Charlotte Hespe & Dr Ramy Bishay

General Practitioner & Endocrinologist

Join Dr Charlotte Hespe and Dr Ramy Bishay for this expert panel webcast presentation, where they will discuss the role of GLP-1 in the management of CKD in T2D.